Abstract 4711

Broad Anti-Tumor Activity of a Novel BET Bromodomain Inhibitor

Abstract

Inhibitors against the bromodomain and extra terminal domain (BET) family of proteins have been pursued as promising oncology agents based on growing understanding of epigenetic control of disease processes. Through scaffold-based and crystallography-guided drug design, we discovered PLX51107, a potent and selective small molecule inhibitor of the BET family bromodomains. PLX51107 is structurally unrelated to the benzodiazepines such as JQ1, I-BET762, and OTX015 and other published BET inhibitors. PLX51107 exhibits low nanomolar potency in blocking interactions mediated by the four BET family proteins BRD2, BRD3, BRD4, and BRDT. Pharmacologic inhibition of BET proteins by PLX51107 suppresses the transcription of genes essential for tumor growth and survival and leads to selective killing of cancer cell lines across a broad range of hematologic malignancies (e.g. leukemia, lymphoma and multiple myeloma). A subset of solid tumors (e.g. melanoma) is also sensitive to growth inhibition by the BET inhibitor PLX51107. Novel biomarkers in these diseases have been identified. PLX51107 is well tolerated and has sufficient potency and oral bioavailability to demonstrate in vivo efficacy in animal models of a variety of tumor types, representing both hematologic and solid tumors of diverse genetic backgrounds. In combination studies, PLX51107 showed potential to improve efficacy (response rates and duration of response) of other anticancer treatments without increasing toxicity. These results support further development of PLX51107 as an epigenetic-based therapy for a variety of cancer indications.

Plexxikon's Discovery Platform Figure 1. Scaffold-Based Drug Discovery ex: BRD4 Activity Scaffold-like Compound **Screening Library** 680nM **Biochemical Assays** Tuned for Low Affinity 🦯 **High Throughput Novel Drug** Co-Crystallography Hits and Leads 9-12 months

Medicinal & Synthetic


Chemist

Computational Modeling

& Analytic Technologies

NRAS

Yan Ma, Ben Powell, Jiazhong Zhang, Ying Zhang, Heidi Carias, Garson Tsang, Songyuan Shi, Hoa Nguyen, Ullrich Schwertschlag, Gaston Habets, Prabha Ibrahim, Wayne Spevak, Chao Zhang, Gideon Bollag Plexxikon Inc., 91 Bolivar Dr., Berkeley, CA



A. Potency of PLX51107 and OTX-015 in biochemical and cell-based assays.

Selectivity profile of PLX51107 and OTX-015 showing percentage inhibition using BROMO scan technology (DiscoveRx, Fremont CA). Image generated using TREEspot[™] Software Tool and reprinted with permission from KINOMEscan®, a division of DiscoveRx Corporation, © DISCOVERX **CORPORATION 2010.**

C. Surface diagram showing PLX51107 and OTX-015 accessing the acetyl binding pocket of BRD4-BD1. D. In vivo activity of PLX51107 and OTX-015 in a BaF3 splenomegaly model.

Figure 3. PLX51107 Inhibits Melanoma Cell Proliferation in vitro

		PLX51107
	Cell Line	IC ₅₀ (μM)
BRAF V600E	MALME-3M	0.405
	SK-MEL-5	0.716
	A2058	1.91
	SK-MEL-28	2.2
	SK-MEL-3	3.77
	UACC-257	4.17
	A375	4.46
S Q61 mutant {	IPC-298	0.884
	SK-MEL-30	0.892
	SK-MEL-2	6.13






Figure 5. PLX51107 + MEK Inhibitor Combinations Suppress IPC298 Growth in vivo



Results



Conclusion

- PLX51107 is a novel BET bromodomain inhibitor that is currently undergoing clinical study (NCT02683395)
- 2. PLX51107, as a single agent and in combination with MEK inhibitor, inhibits melanoma cell growth *in vitro* and *in vivo*.
- 3. Microarray and ChIP-Seq studies identify direct target genes of PLX51107 including the known oncogenes MYC and NRAS, and the melanomainitiating cell marker ABCB5 in melanoma cells.



Plexxikon